Micro Rnas as Potential Biomarkers for Early-Stage Diagnosis of Hyperglycemia Induced Cardiac Autoimmunity

• Published in: The American heart journal Vol. 254; p. 242
• Main Authors: Gul, Rafia, Mushtaq, Iram, Murtaza, Iram
• Format: Journal Article
• Language: English
• Published: Philadelphia Elsevier Inc 01.12.2022; Elsevier Limited
• Subjects: Autoantibodies; Autoimmune diseases; Autoimmunity; Beta cells; Bioinformatics; Biomarkers; Blood glucose; Cardiomyocytes; Congestive heart failure; Cytokines; Diabetes mellitus; Diabetes mellitus (insulin dependent); Endothelium; Fatty acids; FOXO1 protein; Gene expression; Genes; Hyperglycemia; Inflammation; Insulin; Insulin-like growth factor I; Lymphocytes; Lymphocytes T; Medical diagnosis; miRNA; Oxidative stress; p53 Protein; PTEN protein; Runx1 protein; Stat3 protein
• ISSN: 0002-8703; 1097-6744
• DOI: 10.1016/j.ahj.2022.10.029

In autoimmune disorder of Type 1 diabetes mellitus (T1DM), T cells mediated destruction of pancreatic beta cells results in insulin deficiency leads to hyperglycemia. Hyperglycemia induced autoimmunity develops oxidative stress, disrupt endothelium function, causes inflammation by upregulating C- reactive proteins, free fatty acids, and inflammatory cytokines in blood, and cardiac specific autoantibodies result in death of cardiomyocytes. There is a need to further evaluate the relation between hyperglycemia, cardiac autoimmunity, inflammation and find effective target to diagnose cardiac autoimmunity at early stage before progression to heart failure. Micro RNAs (miRNAs) are known to regulate post transcriptional expression of their target genes. We used gene target registry (GTR) for finding genes involved in hyperglycemia induced cardiac autoimmunity. Different miRNAs targeting these genes were identified by using bioinformatics tools NCBI, miRanda, TargetScan, miRBase, and TarBase. With the help of these bioinformatics repositories, we found following genes and their putative miRNAs that targets them by binding at 8mer units: TP53 (let-7i-5p, miR-98-5p), VEGFA (miR-15a-5p, miR-195-5p, miR-424-5p, miR-497-5p, miR-29a-3p), RUNX1 (miR-27a-3p, miR-30a-5p, miR-18a-5p), IGF1 (miR-1-3p, miR-206, miR-29a-3p, let-7a-5p, miR-98-5p, miR-130a-3p, miR-29a-3p), STAT3 (miR-124-3p.1, miR-125a-5p), PTEN (miR-26a-5p, miR-148a-3p, miR-29a-3p, miR-19a-3p, miR-25-3p, miR-22-3p, miR-26a-5p), MAPK14 (miR-128-3p, miR-124-3p.1, miR-124-3p.2, miR-506-3p), PPARG (miR-130b-3p, miR-301a-3p, miR-454-3p), FOXO1 (miR-96-5p, miR-1271-5p, miR-135a-5p), TNFRSF1B (let-7a-5p, miR-98-5p), TCF7L2 (miR-96-5p, miR-1271-5p), PRKCD (miR-26a-5p), ANXA2 (miR-1-3p, miR-206), INSR (let-7a-5p, miR-98-5p), TET2 (miR-153-3p, miR-29a-3p, miR-26a-5p, miR-29a-3p, miR-148a-3p, miR-152-3p), ENTPD1 (miR-135a-5p). In conclusion, we predict that given miRNAs can be investigated as potential miRNA-based early-stage diagnostic biomarkers for the hyper glycemia induced cardiac autoimmunity.